Fortis Healthcare today said it has received an unsolicited non-binding offer from Fosun Health Holdings with a proposal of primary infusion at a price up to Rs 156 per share, up to a total investment of USD 350 million subject to due diligence to be completed within three weeks.
In a late night filing to BSE, Fortis Healthcare said it "has received an unsolicited non-binding expression of interest from Fosun Health Holdings Ltd, a wholly owned subsidiary of Fosun International Ltd...,with a proposal of primary infusion at a price up to Rs 156 per share, subject to due diligence to be completed within three weeks".
This expression of interest is for up to a total investment of USD 350 million (including a preliminary investment of up to Rs 100 crore and further subject to certain conditions, it said.
In another filing Fortis said it has availed a secured financing facility up to Rs 160 crore from RattanIndia Finance Private Ltd on March 29 for a tenor of three years for meeting its working Capital requirements and General Corporate Purposes.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)